Samsung Biologics IPO to raise $2b, move seen as new growth engine for parent

Samsung Biologics IPO to raise $2b, move seen as new growth engine for parent

Samsung Biologics Co. is seeking to raise as much as 2.25 trillion won ($2 billion) from a South Korean initial public offering, taking an important step toward its goal of becoming the world’s largest contract manufacturer of biological medicines.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter